(Q30167833)

9 June 2017

1 reference

title

SH2 and SH3 domains as targets for anti-proliferative agents (English)

1 reference

9 June 2017

0 references

M Vidal

1

0 references

author name string

V Gigoux

series ordinal

2

1 reference

PubMed ID

11682324

9 June 2017

C Garbay

series ordinal

3

1 reference

9 June 2017

1 November 2001

1 reference

Critical Reviews in Oncology Hematology

9 June 2017

1 reference

9 June 2017

40

1 reference

9 June 2017

175-186

1 reference

9 June 2017

2

1 reference

Inhibitors of farnesyl:protein transferase--a possible cancer chemotherapeutic

9 June 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900142-1

7 January 2021

Protein tyrosine kinase inhibitors as novel therapeutic agents

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900142-1

7 January 2021

A noncatalytic domain conserved among cytoplasmic protein-tyrosine kinases modifies the kinase function and transforming activity of Fujinami sarcoma virus P130gag-fps

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900142-1

7 January 2021

SH3 domains. Molecular 'Velcro'.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900142-1

7 January 2021

SH3--an abundant protein domain in search of a function

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900142-1

7 January 2021

SH2/SH3 signaling proteins

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900142-1

7 January 2021

Grb2 mediates the EGF-dependent activation of guanine nucleotide exchange on Ras

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900142-1

7 January 2021

src-homology 2 (SH2) domain ligation as an allosteric regulator: modulation of phosphoinositide-specific phospholipase C gamma 1 structure and activity

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900142-1

7 January 2021

SH2 and SH3 domains: potential targets for anti-cancer drug design

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900142-1

7 January 2021

Involvement of pp60c-src with two major signaling pathways in human breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900142-1

7 January 2021

Characterization of human epidermal growth factor receptor and c-Src interactions in human breast tumor cells

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900142-1

7 January 2021

The SH2 and SH3 domain-containing Nck protein is oncogenic and a common target for phosphorylation by different surface receptors

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900142-1

7 January 2021

The Nck SH2/SH3 adaptor protein: a regulator of multiple intracellular signal transduction events

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900142-1

7 January 2021

Multiple Grb2-protein complexes in human cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900142-1

7 January 2021

Bcr-Abl oncoproteins bind directly to activators of the Ras signalling pathway

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900142-1

7 January 2021

BCR/ABL-induced leukemogenesis causes phosphorylation of Hef1 and its association with Crkl

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900142-1

7 January 2021

Activation of Rac1 by a Crk SH3-binding protein, DOCK180

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900142-1

7 January 2021

Extracellular-regulated kinase activation and CAS/Crk coupling regulate cell migration and suppress apoptosis during invasion of the extracellular matrix

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900142-1

7 January 2021

Dominant-negative mutants of Grb2 induced reversal of the transformed phenotypes caused by the point mutation-activated rat HER-2/Neu

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900142-1

7 January 2021

Receptor-tyrosine-kinase- and G beta gamma-mediated MAP kinase activation by a common signalling pathway

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900142-1

7 January 2021

Inhibition of Grb2 and Crkl proteins results in growth inhibition of Philadelphia chromosome positive leukemic cells

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900142-1

7 January 2021

Solution structure of the SH3 domain of Src and identification of its ligand-binding site

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900142-1

7 January 2021

Crystal structure of a Src-homology 3 (SH3) domain

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900142-1

7 January 2021

Solution structure and ligand-binding site of the SH3 domain of the p85 alpha subunit of phosphatidylinositol 3-kinase

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900142-1

7 January 2021

Solution structure of the SH3 domain of phospholipase C-gamma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900142-1

7 January 2021

Solution structure and ligand-binding site of the carboxy-terminal SH3 domain of GRB2

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900142-1

7 January 2021

Solution structure of GAP SH3 domain by 1H NMR and spatial arrangement of essential Ras signaling-involved sequence.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900142-1

7 January 2021

NMR structure of the N-terminal SH3 domain of GRB2 and its complex with a proline-rich peptide from Sos

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900142-1

7 January 2021

Two binding orientations for peptides to the Src SH3 domain: development of a general model for SH3-ligand interactions

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900142-1

7 January 2021

Proline-rich sequences that bind to Src homology 3 domains with individual specificities

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900142-1

7 January 2021

Structural determinants of peptide-binding orientation and of sequence specificity in SH3 domains

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900142-1

7 January 2021

Specific interactions outside the proline-rich core of two classes of Src homology 3 ligands

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900142-1

7 January 2021

Identification of a ten-amino acid proline-rich SH3 binding site

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900142-1

7 January 2021

Cloning of ligand targets: systematic isolation of SH3 domain-containing proteins

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900142-1

7 January 2021

Distinct ligand preferences of Src homology 3 domains from Src, Yes, Abl, Cortactin, p53bp2, PLCgamma, Crk, and Grb2.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900142-1

7 January 2021

Molecular basis for the binding of SH3 ligands with non-peptide elements identified by combinatorial synthesis

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900142-1

7 January 2021

Exploiting the basis of proline recognition by SH3 and WW domains: design of N-substituted inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900142-1

7 January 2021

Design and synthesis of SH3 domain binding ligands: modifications of the consensus sequence XPpXP.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900142-1

7 January 2021

Identification of D-peptide ligands through mirror-image phage display

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900142-1

7 January 2021

Crystal structure of the mammalian Grb2 adaptor

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900142-1

7 January 2021

DNA polyintercalation: comparison of DNA binding properties of an acridine dimer and trimer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900142-1

7 January 2021

A Sos-derived peptidimer blocks the Ras signaling pathway by binding both Grb2 SH3 domains and displays antiproliferative activity

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900142-1

7 January 2021

Genetic engineering of proteins with cell membrane permeability

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900142-1

7 January 2021

Cell internalization of the third helix of the Antennapedia homeodomain is receptor-independent.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900142-1

7 January 2021

A Truncated HIV-1 Tat Protein Basic Domain Rapidly Translocates through the Plasma Membrane and Accumulates in the Cell Nucleus

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900142-1

7 January 2021

Src homology-2 domains: structure, mechanisms, and drug discovery

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900142-1

7 January 2021

Crystal structure of the phosphotyrosine recognition domain SH2 of v-src complexed with tyrosine-phosphorylated peptides

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900142-1

7 January 2021

Structural basis for specificity of Grb2-SH2 revealed by a novel ligand binding mode

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900142-1

7 January 2021

Progress in the development of inhibitors of SH2 domains

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900142-1

7 January 2021

Recent advances in the design and synthesis of SH2 inhibitors of Src, Grb2 and ZAP-70.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900142-1

7 January 2021

Design, synthesis, and cocrystal structure of a nonpeptide Src SH2 domain ligand

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900142-1

7 January 2021

Design of peptidomimetic ligands for the pp60src SH2 domain

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900142-1

7 January 2021

The formation of a covalent complex between a dipeptide ligand and the src SH2 domain

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900142-1

7 January 2021

Structure-based design, synthesis, and X-ray crystallography of a high-affinity antagonist of the Grb2-SH2 domain containing an asparagine mimetic

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900142-1

7 January 2021

Structure-based design and synthesis of high affinity tripeptide ligands of the Grb2-SH2 domain

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900142-1

7 January 2021

Potent antagonists of the SH2 domain of Grb2: optimization of the X+1 position of 3-amino-Z-Tyr(PO3H2)-X+1-Asn-NH2

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900142-1

7 January 2021

Structural basis for the high affinity of amino-aromatic SH2 phosphopeptide ligands

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900142-1

7 January 2021

Structure-based design of peptidomimetic ligands of the Grb2-SH2 domain

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900142-1

7 January 2021

Structure-based design of a non-peptidic antagonist of the SH2 domain of GRB2

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900142-1

7 January 2021

Small peptides containing phosphotyrosine and adjacent alphaMe-phosphotyrosine or its mimetics as highly potent inhibitors of Grb2 SH2 domain

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900142-1

7 January 2021

Structure-based design and synthesis of phosphinate isosteres of phosphotyrosine for incorporation in Grb2-SH2 domain inhibitors. Part 1

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900142-1

7 January 2021

Structure-based design and synthesis of phosphinate isosteres of phosphotyrosine for incorporation in Grb2-SH2 domain inhibitors. Part 2.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900142-1

7 January 2021

Potent inhibition of Grb2 SH2 domain binding by non-phosphate-containing ligands

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900142-1

7 January 2021

Inhibition of Grb2 SH2 domain binding by non-phosphate-containing ligands. 2. 4-(2-Malonyl)phenylalanine as a potent phosphotyrosyl mimetic

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900142-1

7 January 2021

The Role of 4-phosphonodifluoromethyl- and 4-phosphono-phenylalanine in the selectivity and cellular uptake of SH2 domain ligands

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900142-1

7 January 2021

Selective GRB2 SH2 inhibitors as anti-Ras therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900142-1

7 January 2021

Effect of potent and selective inhibitors of the Grb2 SH2 domain on cell motility

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900142-1

7 January 2021

Src Homology-2 Domains Protect Phosphotyrosyl Residues against Enzymatic Dephosphorylation

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900142-1

7 January 2021

Cyclic peptide inhibitors of phosphatidylinositol 3-kinase p85 SH2 domain binding

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900142-1

7 January 2021

Nonphosphorylated peptide ligands for the Grb2 Src homology 2 domain

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900142-1

7 January 2021

Mononucleoside phosphotriester derivatives with S-acyl-2-thioethyl bioreversible phosphate-protecting groups: intracellular delivery of 3'-azido-2',3'-dideoxythymidine 5'-monophosphate

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900142-1

7 January 2021

Inhibition of the ras-dependent mitogenic pathway by phosphopeptide prodrugs with antiproliferative properties

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900142-1

7 January 2021

Actinomycin D, C2 and VII, inhibitors of Grb2-SHC interaction produced by Streptomyces

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900142-1

7 January 2021

Structure-based design of novel bicyclic nonpeptide inhibitors for the src SH2 domain.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900142-1

7 January 2021

Structure-based design of an osteoclast-selective, nonpeptide src homology 2 inhibitor with in vivo antiresorptive activity

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900142-1

7 January 2021

A Src SH2 selective binding compound inhibits osteoclast-mediated resorption.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900142-1

7 January 2021

Src inhibitors: drugs for the treatment of osteoporosis, cancer or both?

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900142-1

7 January 2021

10.1016/S1040-8428(01)00142-1

Identifiers

DOI

1 reference

release_q3oo4mcwc5cmxfia4sazvdvgae

9 June 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/q3oo4mcwc5cmxfia4sazvdvgae

24 November 2022

mapped directly with Wikidata item

PubMed ID

11682324

1 reference

PubMed ID

11682324